Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing.

Literature DB >> 22378157

Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing.

M A Martin¹, T E Klein, B J Dong, M Pirmohamed, D W Haas, D L Kroetz.

Abstract

Human leukocyte antigen B (HLA-B) is responsible for presenting peptides to immune cells and plays a critical role in normal immune recognition of pathogens. A variant allele, HLA-B*57:01, is associated with increased risk of a hypersensitivity reaction to the anti-HIV drug abacavir. In the absence of genetic prescreening, hypersensitivity affects ~6% of patients and can be life-threatening with repeated dosing. We provide recommendations (updated periodically at http://www.pharmkgb.org) for the use of abacavir based on HLA-B genotype.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2012 PMID： 22378157 PMCID： PMC3374459 DOI： 10.1038/clpt.2011.355

Source DB: PubMed Journal: Clin Pharmacol Ther ISSN： 0009-9236 Impact factor: 6.875

39 in total

1. Severe anaphylactic shock after rechallenge with abacavir without preceding hypersensitivity.

Authors: P H Frissen; J de Vries; H M Weigel; K Brinkman
Journal: AIDS Date: 2001-01-26 Impact factor: 4.177

2. The abacavir hypersensitivity reaction and interruptions in therapy.

Authors: A E Loeliger; H Steel; S McGuirk; W S Powell; S V Hetherington
Journal: AIDS Date: 2001-07-06 Impact factor: 4.177

3. National Marrow Donor Program HLA-matching guidelines for unrelated marrow transplants.

Authors: Carolyn Katovich Hurley; Lee Ann Baxter Lowe; Brent Logan; Chatchada Karanes; Claudio Anasetti; Daniel Weisdorf; Dennis L Confer
Journal: Biol Blood Marrow Transplant Date: 2003-10 Impact factor: 5.742

4. Medical genetics: a marker for Stevens-Johnson syndrome.

Authors: Wen-Hung Chung; Shuen-Iu Hung; Hong-Shang Hong; Mo-Song Hsih; Li-Cheng Yang; Hsin-Chun Ho; Jer-Yuarn Wu; Yuan-Tsong Chen
Journal: Nature Date: 2004-04-01 Impact factor: 49.962

5. Development of abacavir hypersensitivity reaction after rechallenge in a previously asymptomatic patient.

Authors: Hana M El-Sahly
Journal: AIDS Date: 2004-01-23 Impact factor: 4.177

6. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.

Authors: S Mallal; D Nolan; C Witt; G Masel; A M Martin; C Moore; D Sayer; A Castley; C Mamotte; D Maxwell; I James; F T Christiansen
Journal: Lancet Date: 2002-03-02 Impact factor: 79.321

7. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir.

Authors: S Hetherington; S McGuirk; G Powell; A Cutrell; O Naderer; B Spreen; S Lafon; G Pearce; H Steel
Journal: Clin Ther Date: 2001-10 Impact factor: 3.393

8. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir.

Authors: Seth Hetherington; Arlene R Hughes; Michael Mosteller; Denise Shortino; Katherine L Baker; William Spreen; Eric Lai; Kirstie Davies; Abigail Handley; David J Dow; Mary E Fling; Michael Stocum; Clive Bowman; Linda M Thurmond; Allen D Roses
Journal: Lancet Date: 2002-03-30 Impact factor: 79.321

9. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors.

Authors: S A Migueles; M S Sabbaghian; W L Shupert; M P Bettinotti; F M Marincola; L Martino; C W Hallahan; S M Selig; D Schwartz; J Sullivan; M Connors
Journal: Proc Natl Acad Sci U S A Date: 2000-03-14 Impact factor: 11.205

10. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant.

Authors: Annalise M Martin; David Nolan; Silvana Gaudieri; Coral Ann Almeida; Richard Nolan; Ian James; Filipa Carvalho; Elizabeth Phillips; Frank T Christiansen; Anthony W Purcell; James McCluskey; Simon Mallal
Journal: Proc Natl Acad Sci U S A Date: 2004-03-15 Impact factor: 11.205

64 in total

1. Pharmacogenetic testing: Current Evidence of Clinical Utility.

Authors: Jivan Moaddeb; Susanne B Haga
Journal: Ther Adv Drug Saf Date: 2013-08-01

2. Generalized pustular eruptions: time to adapt the disease taxonomy to the genetic architecture?

Authors: Alexander A Navarini; Laurence Valeyrie-Allanore; Niovi Setta-Kaffetzi; Jonathan N Barker; Francesca Capon; Daniel Creamer; Jean-Claude Roujeau; Peggy Sekula; Michael A Simpson; Richard C Trembath; Maja Mockenhaupt; Catherine H Smith
Journal: J Invest Dermatol Date: 2013-08-16 Impact factor: 8.551

Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing.

1. Severe anaphylactic shock after rechallenge with abacavir without preceding hypersensitivity.

2. The abacavir hypersensitivity reaction and interruptions in therapy.

3. National Marrow Donor Program HLA-matching guidelines for unrelated marrow transplants.

4. Medical genetics: a marker for Stevens-Johnson syndrome.

5. Development of abacavir hypersensitivity reaction after rechallenge in a previously asymptomatic patient.

6. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.

7. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir.

8. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir.

9. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors.

10. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant.

1. Pharmacogenetic testing: Current Evidence of Clinical Utility.

2. Generalized pustular eruptions: time to adapt the disease taxonomy to the genetic architecture?

3. Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing.

Review 4. Genetic Testing in Clinical Settings.

5. Clinical Pharmacogenomics: Applications in Nephrology.

6. Pharmacogenetics in clinical practice: how far have we come and where are we going?

Review 7. Pharmacogenomics in dermatology: tools for understanding gene-drug associations.

Review 8. Relating human genetic variation to variation in drug responses.

9. Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing.

10. PharmGKB summary: very important pharmacogene information for human leukocyte antigen B.